<DOC>
	<DOCNO>NCT00290927</DOCNO>
	<brief_summary>- To evaluate superiority efficacy HMR1964 OHA combination therapy compare OHA therapy . - To evaluate superiority efficacy HMR1964 mono-therapy compare OHA therapy . - To evaluate safety HMR1964 .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glulisine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Men woman type 2 diabetes mellitus diagnose least one year prior study BMI &lt; 30 kg/m2 , HbA1C &gt; 8.0 &lt; 11.0 % screen Fasting serum Cpeptide screen &gt; 0.7 ng/mL Subjects stable regimen follow dos SU least 8 week prior sign inform consent Glibenclamide &gt; 5 mg/day Glimepiride &gt; 3 mg/day Gliclazide &gt; 80 mg/day In addition receiving mention SU agent , subject may treat biguanide stable dose least 8 week prior sign inform consent . Subjects willing administer three HMR1964 injection per day immediately prior meal 16 week Subjects unwilling incapable receive start dose ≥ 0.2 IU/kg/day HMR1964 Subjects likelihood require concomitant treatment study period follow class drug : additional OHA ( include thiazolidinediones , αglucosidase inhibitor , Dphenylalanine derivative ) specify study protocol , insulin preparation HMR1964 , systemic corticosteroid , investigational product Subjects clinically relevant cardiovascular , hepatic , neurologic , endocrine disease ; active cancer ; major systemic disease make implementation protocol interpretation study result difficult Subjects pregnant , breast feeding wish become pregnant study period Subjects diabetic retinopathy receive surgical treatment ( laser photocoagulation vitrectomy ) within 12 week prior inform consent , expect surgical treatment study period , diagnose newly proliferative diabetic retinopathy within 12 week prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HMR1964 , insulin glulisine , Diabetes Mellitus , Type 2</keyword>
</DOC>